cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.27050479
title: Supplementary Material for: Selective adjuvant Ayurvedic treatment modulates immune response and oxidative stress in patient with carcinoma of pyriform fossa, undergoing radiotherapy: A case study

description: Introduction - Hypopharyngeal squamous cell carcinoma has poor prognosis with only 25% chances of 5 years of relative survival in such patients in spite of conventional treatment including radical surgery, radiotherapy and concurrent chemotherapy.
Case Presentation – A chronic tobacco - betel nut chewer 62-years-old male patient had dysphagia with hoarseness of voice diagnosed with stage III, grade II malignant pyriform fossa. The patient underwent 9 cycles of neo adjuvant chemotherapy with Inj Paclitaxel 100 mg and Inj Cisplatin 40 mg. He was then referred to our institute for Radical Radiotherapy with Concurrent Chemotherapy with adjunct Ayurvedic treatment. A total dose of 70 Gy of radiation with cobalt 60 source was administered to the bilateral face and neck, in 35 fractions. Patient also received 6 cycles of concurrent weekly chemotherapy with Inj Cisplatin 40 mg. He received well planned adjunct Ayurvedic treatment in the form of Oral Ayurvedic Medicines (OAM) and Detoxifying treatment, Panchakarma. All the measured adverse effects of radiotherapy such as Stomatitis, Xerostomia, Taste Alteration, Dysphagia, Nausea etc. were observed to be remarkably low during and post radiotherapy in this patient. Karnofsky and QoL scores revealed patient’s wellbeing throughout the treatment course. After 5 years PET CT scan revealed no FDG avid loco regional recurrence or distant organ involvement implying Disease Free Survival (DFS). Various Chemokines, cytokines and oxidative stress were assessed during the course of treatment to observe tumour microenvironment.
Conclusion – Present case of HNC, Stage III and Grade II belonged to high-grade, high-risk hypopharyngeal cancer with poor prognosis. The patient opted for Ayurvedic treatment besides radiotherapy which continued thereafter for 5 years. We therefore emphasize that in this case, minimum side effects of radiotherapy, immunomodulation and reduction in inflammation and oxidative stress along with good quality of life can be attributed to OAM and repeated detoxifying Panchakarma treatment supported with healthy diet and good lifestyle. The highlight of the study is the marked effect on the patient’s immune response and reduction in oxidative stress leading to 5 years and beyond of DFS.
DOI: 10.6084/m9.figshare.27050479.v1
title: Supplementary Material for: Selective adjuvant Ayurvedic treatment modulates immune response and oxidative stress in patient with carcinoma of pyriform fossa, undergoing radiotherapy: A case study

description: Introduction - Hypopharyngeal squamous cell carcinoma has poor prognosis with only 25% chances of 5 years of relative survival in such patients in spite of conventional treatment including radical surgery, radiotherapy and concurrent chemotherapy.
Case Presentation – A chronic tobacco - betel nut chewer 62-years-old male patient had dysphagia with hoarseness of voice diagnosed with stage III, grade II malignant pyriform fossa. The patient underwent 9 cycles of neo adjuvant chemotherapy with Inj Paclitaxel 100 mg and Inj Cisplatin 40 mg. He was then referred to our institute for Radical Radiotherapy with Concurrent Chemotherapy with adjunct Ayurvedic treatment. A total dose of 70 Gy of radiation with cobalt 60 source was administered to the bilateral face and neck, in 35 fractions. Patient also received 6 cycles of concurrent weekly chemotherapy with Inj Cisplatin 40 mg. He received well planned adjunct Ayurvedic treatment in the form of Oral Ayurvedic Medicines (OAM) and Detoxifying treatment, Panchakarma. All the measured adverse effects of radiotherapy such as Stomatitis, Xerostomia, Taste Alteration, Dysphagia, Nausea etc. were observed to be remarkably low during and post radiotherapy in this patient. Karnofsky and QoL scores revealed patient’s wellbeing throughout the treatment course. After 5 years PET CT scan revealed no FDG avid loco regional recurrence or distant organ involvement implying Disease Free Survival (DFS). Various Chemokines, cytokines and oxidative stress were assessed during the course of treatment to observe tumour microenvironment.
Conclusion – Present case of HNC, Stage III and Grade II belonged to high-grade, high-risk hypopharyngeal cancer with poor prognosis. The patient opted for Ayurvedic treatment besides radiotherapy which continued thereafter for 5 years. We therefore emphasize that in this case, minimum side effects of radiotherapy, immunomodulation and reduction in inflammation and oxidative stress along with good quality of life can be attributed to OAM and repeated detoxifying Panchakarma treatment supported with healthy diet and good lifestyle. The highlight of the study is the marked effect on the patient’s immune response and reduction in oxidative stress leading to 5 years and beyond of DFS.
DOI: 10.15468/dl.2tdcge
title: Occurrence Download

description: A dataset containing 63 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Rhodiola rosea L."
 ]
}

 The dataset includes 63 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0021273-241007104925546/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hpk6nx
title: Occurrence Download

description: A dataset containing 13545 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Lolium temulentum L."
 ]
}

 The dataset includes 13545 records from 581 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0021274-241007104925546/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.27023851
title: Supplementary Material for: Head-up Tilt Sleeping to Treat Orthostatic Intolerance in a Patient with Advanced Parkinson’s Disease: A Case Report

description: Introduction: Orthostatic hypotension is common in people with Parkinson’s disease due to autonomic dysfunction and medication use, and can have a significant negative impact on quality of life. Pharmacological treatment is often complicated due to complex blood pressure regulation problems. This case report presents a patient whose symptoms of orthostatic intolerance were successfully treated with the non-pharmacological method of Head-Up Tilt Sleeping (HUTS).
Case presentation: A 69-year-old man with Parkinson’s disease and prominent autonomic failure received recommendation from the neurologist to use HUTS to battle orthostatic intolerance, of which complaints were worst in the early morning. The patient noted a marked improvement of the orthostatic intolerance after a period in which he slowly step-by-step inclined the bed to an angle just over 10°. When ceasing HUTS for a brief period, complaints of orthostatic intolerance immediately returned and the patient returned to tilted sleeping right away. After a follow-up of three months the patient did not report orthostatic intolerance during a standing test. 
Conclusion: This case illuminates that, despite difficulties intrinsic to this method, whole-body head-up tilt sleeping can ameliorate orthostatic intolerance and improve the daily life of people with advanced movement disorders.
DOI: 10.6084/m9.figshare.27023851.v2
title: Supplementary Material for: Head-up Tilt Sleeping to Treat Orthostatic Intolerance in a Patient with Advanced Parkinson’s Disease: A Case Report

description: Introduction: Orthostatic hypotension is common in people with Parkinson’s disease due to autonomic dysfunction and medication use, and can have a significant negative impact on quality of life. Pharmacological treatment is often complicated due to complex blood pressure regulation problems. This case report presents a patient whose symptoms of orthostatic intolerance were successfully treated with the non-pharmacological method of Head-Up Tilt Sleeping (HUTS).
Case presentation: A 69-year-old man with Parkinson’s disease and prominent autonomic failure received recommendation from the neurologist to use HUTS to battle orthostatic intolerance, of which complaints were worst in the early morning. The patient noted a marked improvement of the orthostatic intolerance after a period in which he slowly step-by-step inclined the bed to an angle just over 10°. When ceasing HUTS for a brief period, complaints of orthostatic intolerance immediately returned and the patient returned to tilted sleeping right away. After a follow-up of three months the patient did not report orthostatic intolerance during a standing test. 
Conclusion: This case illuminates that, despite difficulties intrinsic to this method, whole-body head-up tilt sleeping can ameliorate orthostatic intolerance and improve the daily life of people with advanced movement disorders.
DOI: 10.6084/m9.figshare.27023851.v1
title: Supplementary Material for: Head-up Tilt Sleeping to Treat Orthostatic Intolerance in a Patient with Advanced Parkinson’s Disease: A Case Report

description: Introduction: Orthostatic hypotension is common in people with Parkinson’s disease due to autonomic dysfunction and medication use, and can have a significant negative impact on quality of life. Pharmacological treatment is often complicated due to complex blood pressure regulation problems. This case report presents a patient whose symptoms of orthostatic intolerance were successfully treated with the non-pharmacological method of Head-Up Tilt Sleeping (HUTS).
Case presentation: A 69-year-old man with Parkinson’s disease and prominent autonomic failure received recommendation from the neurologist to use HUTS to battle orthostatic intolerance, of which complaints were worst in the early morning. The patient noted a marked improvement of the orthostatic intolerance after a period in which he slowly step-by-step inclined the bed to an angle just over 10°. When ceasing HUTS for a brief period, complaints of orthostatic intolerance immediately returned and the patient returned to tilted sleeping right away. After a follow-up of three months the patient did not report orthostatic intolerance during a standing test. 
Conclusion: This case illuminates that, despite difficulties intrinsic to this method, whole-body head-up tilt sleeping can ameliorate orthostatic intolerance and improve the daily life of people with advanced movement disorders.
DOI: 10.57967/hf/3274
title: LCC_Cesium_Test
DOI: 10.6084/m9.figshare.27223608
title: Supplementary Material for: The Efficacy and Safety of Stepwise Oral Food Challenge in Children with Cow’s Milk Allergy

description: <b><i>Introduction:</i></b> Stepwise oral food challenge (OFC) tests begin with low doses of allergens and progress to full doses. We previously reported the safety and efficacy of stepwise OFC for reintroducing hen eggs. In this study, we discuss its application for cow’s milk (CM) allergy. <b><i>Methods:</i></b> We included 927 children (median age, 3.2 years) who underwent CM-OFC between 2017 and 2021. The target challenge dose was classified as low (&lt;10 mL), middle (≥10 mL but &lt;100 mL), or full. When participants reacted to the low dose, they underwent a very low-dose OFC using baked milk or &lt;1 mL of CM. <b><i>Results:</i></b> Positive reactions occurred in 210 cases (22.7%), including 69 anaphylactic reactions (7.4%). A lower target dose resulted in more positive OFC results (<i>p</i> &lt; 0.001) and anaphylaxis (<i>p</i> = 0.001). The lower dose group included more children with complete elimination of CM (<i>p</i> &lt; 0.001), with numerous histories of anaphylaxis induced by CM (<i>p</i> &lt; 0.001), and higher levels of total IgE (<i>p</i> = 0.033) and CM-sIgE (<i>p</i> &lt; 0.001). A multivariate analysis indicated that in the low-dose-OFC group, higher CM-sIgE levels (<i>p</i> = 0.034), younger age (<i>p</i> = 0.005), and complete elimination of CM (<i>p</i> = 0.002) were associated with positive OFC results. <b><i>Conclusion:</i></b> The stepwise OFC could reintroduce small amounts of CM, even in cases with high CM-sIgE levels or a history of anaphylaxis. Performing CM-OFC at younger ages, specifically from infancy, with very low doses, might facilitate the safe reintroduction of CM.
DOI: 10.6084/m9.figshare.27223608.v1
title: Supplementary Material for: The Efficacy and Safety of Stepwise Oral Food Challenge in Children with Cow’s Milk Allergy

description: <b><i>Introduction:</i></b> Stepwise oral food challenge (OFC) tests begin with low doses of allergens and progress to full doses. We previously reported the safety and efficacy of stepwise OFC for reintroducing hen eggs. In this study, we discuss its application for cow’s milk (CM) allergy. <b><i>Methods:</i></b> We included 927 children (median age, 3.2 years) who underwent CM-OFC between 2017 and 2021. The target challenge dose was classified as low (&lt;10 mL), middle (≥10 mL but &lt;100 mL), or full. When participants reacted to the low dose, they underwent a very low-dose OFC using baked milk or &lt;1 mL of CM. <b><i>Results:</i></b> Positive reactions occurred in 210 cases (22.7%), including 69 anaphylactic reactions (7.4%). A lower target dose resulted in more positive OFC results (<i>p</i> &lt; 0.001) and anaphylaxis (<i>p</i> = 0.001). The lower dose group included more children with complete elimination of CM (<i>p</i> &lt; 0.001), with numerous histories of anaphylaxis induced by CM (<i>p</i> &lt; 0.001), and higher levels of total IgE (<i>p</i> = 0.033) and CM-sIgE (<i>p</i> &lt; 0.001). A multivariate analysis indicated that in the low-dose-OFC group, higher CM-sIgE levels (<i>p</i> = 0.034), younger age (<i>p</i> = 0.005), and complete elimination of CM (<i>p</i> = 0.002) were associated with positive OFC results. <b><i>Conclusion:</i></b> The stepwise OFC could reintroduce small amounts of CM, even in cases with high CM-sIgE levels or a history of anaphylaxis. Performing CM-OFC at younger ages, specifically from infancy, with very low doses, might facilitate the safe reintroduction of CM.
DOI: 10.5281/zenodo.13948984
title: ИССЛЕДОВАНИЕ ВЛИЯНИЯ ЭКСТРАКТА ШАФРАНА НА КОГНИТИВНЫЕ НАРУШЕНИЯ
DOI: 10.5281/zenodo.13948985
title: ИССЛЕДОВАНИЕ ВЛИЯНИЯ ЭКСТРАКТА ШАФРАНА НА КОГНИТИВНЫЕ НАРУШЕНИЯ
DOI: 10.6084/m9.figshare.27013867
title: Supplementary Material for: Poor tolerability of lenvatinib in elderly patients with advanced hepatocellular carcinoma after disease progression following first-line atezolizumab plus bevacizumab: A multicenter study

description: Introduction: We investigated the effectiveness of lenvatinib (LEN) after disease progression
following first-line treatment with atezolizumab plus bevacizumab (Atez/Bev) in patients with
unresectable hepatocellular carcinoma (HCC).
Methods: One hundred and ten HCC patients treated with Atez/Bev as first-line systemic chemotherapy were enrolled and underwent dynamic computerized tomography/magnetic resonance imaging to determine the treatment response. We evaluated the treatment efficacy and prognosis after second-line LEN treatment especially in the elderly patients.
Results: Of the 110 study patients, 88 patients (80%) were determined to have progressive disease (PD) during the observation periods, and 40 patients received second-line LEN therapy. The 40 patients included 13 patients who were unable to continue LEN until the initial evaluation due to adverse events (AE). The 27 patients who were able to continue LEN therapy (Group A) were significantly younger at initiation of Atez/Bev than those who could not continue (71 vs. 77 years old, P = 0.013). Comparing the OS and PFS between Group A and 44 patients that included 13 patients who were unable to continue LEN and 31 patients did not receive the second-line treatment (Group B), the former had significantly better OS than Group B (31.1 vs. 17.8 months, P = 0.035)
Conclusions: The tolerability of second-line LEN therapy was lower in elderly patients, and the OS from the start of Atez/Bev therapy was different depending on the tolerability to second-line LEN therapy.
DOI: 10.6084/m9.figshare.27013867.v1
title: Supplementary Material for: Poor tolerability of lenvatinib in elderly patients with advanced hepatocellular carcinoma after disease progression following first-line atezolizumab plus bevacizumab: A multicenter study

description: Introduction: We investigated the effectiveness of lenvatinib (LEN) after disease progression
following first-line treatment with atezolizumab plus bevacizumab (Atez/Bev) in patients with
unresectable hepatocellular carcinoma (HCC).
Methods: One hundred and ten HCC patients treated with Atez/Bev as first-line systemic chemotherapy were enrolled and underwent dynamic computerized tomography/magnetic resonance imaging to determine the treatment response. We evaluated the treatment efficacy and prognosis after second-line LEN treatment especially in the elderly patients.
Results: Of the 110 study patients, 88 patients (80%) were determined to have progressive disease (PD) during the observation periods, and 40 patients received second-line LEN therapy. The 40 patients included 13 patients who were unable to continue LEN until the initial evaluation due to adverse events (AE). The 27 patients who were able to continue LEN therapy (Group A) were significantly younger at initiation of Atez/Bev than those who could not continue (71 vs. 77 years old, P = 0.013). Comparing the OS and PFS between Group A and 44 patients that included 13 patients who were unable to continue LEN and 31 patients did not receive the second-line treatment (Group B), the former had significantly better OS than Group B (31.1 vs. 17.8 months, P = 0.035)
Conclusions: The tolerability of second-line LEN therapy was lower in elderly patients, and the OS from the start of Atez/Bev therapy was different depending on the tolerability to second-line LEN therapy.
DOI: 10.6084/m9.figshare.27254952
title: Supplementary Material for: Calciphylaxis Mimicking Giant Cell Arteritis: A Case Report

description: <b><i>Introduction:</i></b> Calciphylaxis is a condition that causes vascular calcification and intimal proliferation with thrombotic occlusion of small-to-medium-sized vessels. <b><i>Case Presentation:</i></b> We describe a case of a 64-year-old woman who presented with a clinical picture that was suggestive of anterior arteritic ischemic optic neuropathy due to giant cell arteritis (GCA), but was found to have calciphylaxis confirmed by histologic examination. When calciphylaxis affects the blood supply to the eye, commonly it causes sudden vision loss, pallid optic disk edema, and a relative afferent pupillary defect, all of which were observed in our patient. <b><i>Conclusion:</i></b> There is no known cure for calciphylaxis, while in GCA, high-dose corticosteroid therapy is essential to prevent involvement of the contralateral eye. As the management approaches for these two diseases are different, it is important to have performed a thorough clinical examination along with detailed histopathological testing to rule out calciphylaxis of the temporal artery in patients suspected to have GCA.
DOI: 10.6084/m9.figshare.27254952.v1
title: Supplementary Material for: Calciphylaxis Mimicking Giant Cell Arteritis: A Case Report

description: <b><i>Introduction:</i></b> Calciphylaxis is a condition that causes vascular calcification and intimal proliferation with thrombotic occlusion of small-to-medium-sized vessels. <b><i>Case Presentation:</i></b> We describe a case of a 64-year-old woman who presented with a clinical picture that was suggestive of anterior arteritic ischemic optic neuropathy due to giant cell arteritis (GCA), but was found to have calciphylaxis confirmed by histologic examination. When calciphylaxis affects the blood supply to the eye, commonly it causes sudden vision loss, pallid optic disk edema, and a relative afferent pupillary defect, all of which were observed in our patient. <b><i>Conclusion:</i></b> There is no known cure for calciphylaxis, while in GCA, high-dose corticosteroid therapy is essential to prevent involvement of the contralateral eye. As the management approaches for these two diseases are different, it is important to have performed a thorough clinical examination along with detailed histopathological testing to rule out calciphylaxis of the temporal artery in patients suspected to have GCA.
DOI: 10.5281/zenodo.13932987
title: BioTISR: Microtubules (3D)

description: 3D microtubules data of BioTISR dataset.

BioTISR is a biological image dataset for super-resolution microscopy, currently including 2D and 3D time-lapse image pairs of low-and-high resolution images of a variety of biology structures, aiming to provide a high-quality dataset of time-lapse biological SR images for the community to spark more developments of computational SR methods.

At present, 2D dataset includes five specimens (clathrin-coated pits, lysosomes, outer mitochondrial membrane, microtubules, and F-actin) acquired with the GI/TIRF-SIM mode and nonlinear SIM mode of our Multi-SIM system, and 3D data includes three specimens (outer mitochondrial membrane, microtubules, and F-actin) acquired with 3D-SIM mode of the Multi-SIM system. For each type of specimen and each imaging modality, we acquired the raw data from at least 50 distinct regions-of-interest (ROI). For each ROI, we acquired two (3D data) or three (2D data) groups of N-phase × M-orientation × T-timepoint raw images with a constant exposure time but increasing the excitation light intensity, where (N, M, T) are (3, 3, 20) for TIRF-SIM and GI-SIM, (5, 5, 10) for nonlinear SIM, and (3, 5, 10) for 3D-SIM.

The BioTISR dataset is related to the following paper:Chang Qiao, Shuran Liu, Yuwang Wang, Wencong Xu, et al. "Time-lapse Image Super-resolution Neural Network with Reliable Confidence Evaluation for Optical Microscopy." bioRxiv 2024.05.04.592503 (2024), which is an extension of our previously published BioSR dataset (https://www.nature.com/articles/s41592-020-01048-5).
DOI: 10.5281/zenodo.13932988
title: BioTISR: Microtubules (3D)

description: 3D microtubules data of BioTISR dataset.

BioTISR is a biological image dataset for super-resolution microscopy, currently including 2D and 3D time-lapse image pairs of low-and-high resolution images of a variety of biology structures, aiming to provide a high-quality dataset of time-lapse biological SR images for the community to spark more developments of computational SR methods.

At present, 2D dataset includes five specimens (clathrin-coated pits, lysosomes, outer mitochondrial membrane, microtubules, and F-actin) acquired with the GI/TIRF-SIM mode and nonlinear SIM mode of our Multi-SIM system, and 3D data includes three specimens (outer mitochondrial membrane, microtubules, and F-actin) acquired with 3D-SIM mode of the Multi-SIM system. For each type of specimen and each imaging modality, we acquired the raw data from at least 50 distinct regions-of-interest (ROI). For each ROI, we acquired two (3D data) or three (2D data) groups of N-phase × M-orientation × T-timepoint raw images with a constant exposure time but increasing the excitation light intensity, where (N, M, T) are (3, 3, 20) for TIRF-SIM and GI-SIM, (5, 5, 10) for nonlinear SIM, and (3, 5, 10) for 3D-SIM.

The BioTISR dataset is related to the following paper:Chang Qiao, Shuran Liu, Yuwang Wang, Wencong Xu, et al. "Time-lapse Image Super-resolution Neural Network with Reliable Confidence Evaluation for Optical Microscopy." bioRxiv 2024.05.04.592503 (2024), which is an extension of our previously published BioSR dataset (https://www.nature.com/articles/s41592-020-01048-5).
DOI: 10.5281/zenodo.13948989
title: ВЛИЯНИЕ АСФЕРВОНА НА БИЛИРУБИН ВЫДЕЛИТЕЛЬНУЮ ФУНКЦИЮ ПЕЧЕНИ ПРИ ОСТРОМ ТОКСИЧЕСКОМ ГЕПАТИТЕ РАЗЛИЧНОЙ ЭТИОЛОГИИ
DOI: 10.5281/zenodo.13948990
title: ВЛИЯНИЕ АСФЕРВОНА НА БИЛИРУБИН ВЫДЕЛИТЕЛЬНУЮ ФУНКЦИЮ ПЕЧЕНИ ПРИ ОСТРОМ ТОКСИЧЕСКОМ ГЕПАТИТЕ РАЗЛИЧНОЙ ЭТИОЛОГИИ